Considering that MYC is highly expressed in some cancers, such as breast cancer [68] and neuroblastoma [80], the search for inhibitors of mitochondrial fusion opens a new approach for these types of cancer as MYLS22 (OPA1 inhibitor) recently reported by Scorrano’s group [79]. Here, MYC is linked to breast cancer.